Akeso (9926.HK) Financial Analysis & Valuation | Quarter Chart
Akeso (9926.HK)
9926.HKPrice: $13.1
Fair Value: 🔒
🔒score
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), no... more
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes the... more
Description
Shares
| Market Cap | $12.05B | Exchange | HKSE |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CN | CEO | Baiyong Li |
| IPO Date | 2020-04-24 | CAGR | 1.7% |
| Employees | 3,035 | Website | www.akesobio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 1.09% | Total Yield | 1.09% |
9926.HK chart loading...
Fundamentals
Technicals
| Enterprise Value | $87.08B | P/E Ratio | -71.82 |
| Forward P/E | 53.14 | PEG Ratio | — |
| P/S Ratio | 28.14 | P/B Ratio | 9.32 |
| P/CF Ratio | -78.25 | P/FCF Ratio | -62.4 |
| EPS | $-0.18 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -3.94% | Gross Margin | 0.79% |
| Operating Margin | -0.3% | Profit Margin | -0.36% |
| ROE | -0.14% | ROA | -0.07% |
| ROCE | -0.06% | Current Ratio | 5.14 |
| Quick Ratio | 4.71 | Cash Ratio | 4.02 |
| Debt/Equity | 0.5 | Interest Coverage | -13.47 |
| Altman Z Score | 8.46 | Piotroski Score | 2 |